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Abstract
Focal segmental glomerulosclerosis (FSGS) is a histological 
pattern of podocyte and glomerulus injury. FSGS can be pri-
mary and secondary to other diseases or due to a genetic 
cause. Strikingly, genetic causes for adult-onset FSGS are of-
ten overlooked, likely because identifying patients with ge-
netic forms of FSGS based on clinical presentation and histo-
pathology is difficult. Yet diagnosing genetic FSGS does not 
only have implications for prognostication and therapy but 
also for family and family planning. In this case series, we 
present 3 adult patients who presented with advanced renal 
disease with the histological picture of FSGS and proved to 
have a genetic cause of the disease, namely, variants in INF2, 
COL4A4 and HNF1B, respectively. We show the possibilities 
of identifying genetic FSGS based on clinical clues of a posi-
tive family history, early age at onset of disease, and/or se-
vere therapy-resistant disease. We discuss ways to select the 
method of genetic testing for individual patients. Finally, we 
examine how the judicious use of genetic investigations can 
obviate potential harmful diagnostic procedures and direct 
clinical decisions in patients and their relatives.
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Background
With the advances in genetic testing methods, genetic 
analysis is an increasingly important diagnostic tool in 
nephrology [1]. This is also the case for genetic focal seg-
mental glomerulosclerosis (FSGS), which is the focus of 
this paper.
FSGS is a histological pattern of podocyte loss and glo-
merular injury. It is characterized in a renal biopsy, by 
segmental sclerotic lesions in at least one glomerulus (ob-
served with light microscopy) and effacement of the 
podocyte foot processes (observed with electron micros-
copy [EM]) [2, 3]. The underlying causes for FSGS are 
heterogeneous [4, 5].
FSGS is traditionally categorized according to those 
underlying causes, namely, primary (often involves a 
circulating factor causing podocyte dysfunction) and 
secondary to a nonrenal disease and genetic FSGS [4, 
6]. Depending on the underlying cause, the patients can 
present with proteinuria, or nephrotic syndrome (most 
in primary FSGS), and end-stage renal disease (ESRD), 
or progress to ESRD over the course of 5–10 years [7].
There are no clear-cut clinical or histopathological 
findings to distinguish genetic FSGS from other 
types [8]. However, there are several hallmarks of ge-
netic disease. Namely a positive family history, early age 
at onset of disease (~30% of FSGS with an onset before 
25 years of age is genetic), and uncharacteristically se-
vere and/or steroid-resistant disease [8–11]. Converse-
ly, because genetic disease often presents at a young age, 
it is often unjustly overlooked in adult-onset FSGS pa-
tients [11].
With the advances of genetic testing, however, diag-
nosing genetic FSGS has become much more feasible over 
the past few years. Not only because over 50 genes are 
currently known to be involved in FSGS, but also since 
the costs and turn-around time for genetic tests are con-
tinuously dropping, increasing their availability in daily 
clinical practice [8, 11–15].
The technique most frequently used for genetic testing 
is next-generation sequencing (NGS) [8, 11–14]. NGS 
can identify disease-causing mutations in the entire ge-
nome (whole-genome sequencing), the protein-coding 
regions (whole-exome sequencing), or a specific set of 
genes of interest (targeted gene panel [TGP]) [16]. For 
instance, the TGP on FSGS in online supplemental Table 
1 (for all online suppl. material, see www.karger.com/
doi/10.1159/000499937) contains the classic FSGS genes 
NPHS1 and NPHS2 as well as genes recently associated 
with FSGS such as the COL4A3–5 genes (the Alport syn-
drome genes) and PAX2 (involved in nephrogenesis). Se-
lecting the right NGS test is essential, to be able to come 
to a diagnosis with limited risk of the incidental findings 
that testing many genes (e.g., whole-exome sequencing) 
can bring.
Despite the abovementioned challenges, considering a 
genetic cause in adult-onset FSGS patients is important 
as it can have a large impact on the patient and his/her 
family members. Here, we present 3 patients with adult-
onset chronic kidney disease who were clinically and his-
topathologically diagnosed with FSGS and were shown to 
carry a genetic cause thanks to a close collaboration be-
tween nephrologists, pathologists, and clinical geneti-
cists. We use these cases to discuss the expanding possi-
bilities of diagnosing genetic FSGS and the clinical impli-
cations of such a diagnosis.
Case 1: FSGS with ESRD at a Young Age
A 30-year-old man with asymptomatic 2 g/day proteinuria at 
age 20 and ESRD at age 29 (no signs of nephrotic syndrome, Table 
1) was referred to our nephrogenetics out-patient clinic. There was 
no family history of renal disease. Renal biopsy at age 29, when the 
patient developed ESRD, showed FSGS (Fig. 1a), with 80% glob-
ally sclerosed glomeruli and partial podocyte foot process efface-
ment (Fig.  1d) [17]. The patient was referred because he was 
planned to undergo a kidney transplant from a family member.
Due to the young age of onset of proteinuria in this patient, 
there was a marked probability of genetic FSGS, and a diagnostic 
TGP analysis for FSGS was performed (online suppl. Methods 1 
and Table 1). This revealed a heterozygous known pathogenic mu-
tation in the INF2 gene (OMIM610982, Table 2) [18–21]. The mu-
tation had been previously detected in FSGS patients, though one 
should note that no functional assessment of that specific mutation 
was performed [18]. Mutations in INF2 are known to be a major 
cause for autosomal dominant FSGS [22–24].
To adequately counsel family members, segregation analysis 
was performed in the patient’s healthy parents. The father did not 
carry the mutation and later successfully donated a kidney to our 
patient. In the otherwise healthy mother, a 20% mosaicism for the 
INF2 mutation was detected in DNA from peripheral blood. The 
mother was referred for extensive health screening, which revealed 
no abnormalities. Since she had had a son with INF2 mutation, it 
must therefore be present in the germline and thus possibly have 
been passed down to the patient’s siblings. One sibling decided on 
testing (revealing no INF2 mutation) and one decided to undergo 
periodic evaluation of renal function. The patient’s young child 
will be counseled regarding presymptomatic genetic testing when 
it is of age. As the earliest presentation reported in literature is at 
7 years of age, the child will undergo proteinuria screening [25].
Next to the implications for family members, the molecular 
diagnosis impacted the patient’s care directly. Mutations in INF2 
can also be associated with dominant intermediate Charcot-Ma-
rie-Tooth disease, thus the patient was neurologically evaluated, 
showing no abnormalities [26]. Additionally, the patient and his 




partner wanted to have more children. After counseling, they opt-
ed to try to conceive via preimplantation genetic diagnostics, an in 
vitro fertilization procedure where an embryo without the INF2 
mutation is transferred into the uterus [27]. At time of this publi-
cation, this has not yet led to an ongoing pregnancy.
Case 2: FSGS with a Family History of ESRD
A 50-year-old obese woman (BMI 34) of Hindustani Surinam 
descent (Table 1) presented in the referring hospital with mild 
chronic kidney disease (eGFR = 90), distinct proteinuria (1.6 g/
day, no signs of nephrotic syndrome), and erythrocyturia of 30 
cells/µL. Her parents had ESRD, both with an age of onset around 
60 years, of which the father was diagnosed as having diabetic ne-
phropathy. In our patient, renal biopsy displayed FSGS (Fig. 1b), 
with 50% globally sclerosed glomeruli, thought to be secondary to 
a metabolic syndrome. However, because of the erythrocyturia, the 
referring nephrologist wondered if COL4A3–5-related disease 
(mutations in these genes are detected in patients with thin base-
ment membrane nephropathy and classical Alport syndrome) 
might play a role in this patient’s phenotype.
To assess this possibility, the renal biopsy was revised with 
EM. This showed a thin GBM with a mean thickness of 172 nm, 
(Fig. 1e), which was well below the lower limit of 252 nm deter-
mined in our center for normal GBM thickness for females and 
also below the lower limit of 215 nm for the normal thickness for 
females reported in literature, further pointing toward COL4A3–
5-related disease [28, 29]. Therefore, the diagnostic TGP analysis 
on FSGS was performed (online suppl. Methods and Table 1). 
This analysis includes the COL4A genes, since mutations in these 
genes have been shown to cause a histological FSGS phenotype in 
some cases [28, 30–34]. The TGP analysis showed a heterozygous 
likely pathogenic mutation in the COL4A4 gene (OMIM120131, 
Table 2), with no variants in other FSGS-linked genes [19–21].
COL4A4 codes for the type IV collagen alpha-4 chain, a protein 
essential to the GBM [35]. Heterozygous mutations in COL4A4 
have been associated with familial hematuria [36]. There are re-
ports suggesting that specific mutations in COL4A4 or unknown 
Table 1. Age at first presentation, laboratory findings, and morphological findings per case
Case
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No immunoreactivity No material FSGS NOS
APTT, activated partial thromboplastin time; CKD, chronic kidney disease; eGFR, electronic glomerular filtration rate; FSGS, focal segmental glomerulosclerosis; Ig, immuno-
globulin; NOS, not otherwise specified; PT, prothrombin time; SRNS, steroid-resistant nephrotic syndrome.
Snoek et al.Nephron 2019;142:351–358354
DOI: 10.1159/000499937
genetic modifiers might cause FSGS lesions in heterozygous carri-
ers, while others suggest that heterozygous COL4A3–5 mutations 
are the most frequent underlying cause in patients with FSGS on 
biopsy [37–40]. It is clear that the penetrance of renal disease in 
carriers of heterozygous COL4A3–4 mutations is far from com-
plete [37–40]. There is debate over whether this is best called au-
tosomal dominant Alport syndrome, or for example, COL4A3–
4-related disease [37–40].
The specific mutation detected in our patient has not been de-
scribed as pathogenic before. However, the variant causes the sub-
stitution of a highly conserved glycine residue in the collagen tri-
ple-helix repeat by a more bulky amino acid (Table 2). Based on 
the fact that most known pathogenic mutations in COL4A4 lead 
to similar substitutions, the mutation was classified as “likely 
pathogenic.” Segregation analysis was performed, and the mother 
(no diabetes) proved to be a carrier for the same mutation. The 
presence of the COL4A4 variant in 2 affected family members, 
along with erythrocyturia and a thin GBM, likely explains at least 
a part of our patient’s  COL4A3–5-related disease phenotype. With 
this, it is important to note that people of Hindustani Surinam 
descent are known to have higher risk of metabolic syndrome, 
which likely also played a role in this family’s renal phenotype(s) 
[37, 41].
Genetic counseling was offered to the patient’s children. Fur-
thermore, the finding of a COL4A4 likely pathogenic variant trig-
gered the referring nephrologist to prescribe Lisinopril, as the pa-
tient needed antihypertensive medication and ACE-inhibition is 
also used to attenuate renal function decline in Alport syndrome 
[42].
Case 3: “IgA-Related FSGS” with a Family  
History of ESRD
An otherwise healthy 33-year-old man presented with an eGFR 
of 39 and proteinuria (0.6 g/day, no signs of nephrotic syndrome). 
The family history revealed that the mother had died with ESRD 
*
*




Fig. 1. Kidney biopsy images in the 3 cases. Light microscopy 
(Jones staining) showed glomeruli with segmental sclerosis (ar-
rows) in case 1 (a), case 2 (b), and case 3 (c). Electron microscopy 
of case 1 showed partial foot process effacement, with areas of in-
tact foot processes (*) alternating with areas with foot process ef-
facement (arrows, d). In addition to partial foot process efface-
ment, EM of case 2 also showed a thin GBM thickness with a mean 

















at age 50, most likely due to hypodysplastic kidneys. Renal ultra-
sound in the patient showed no abnormalities and normal sized 
kidneys (Table 1). In the referring hospital, renal biopsy was clas-
sified as FSGS secondary to IgA depositions. The patient wondered 
if he could pass on the disease to his children.
Biopsy revision at our facility showed FSGS (Fig. 1c) with 45% 
of glomeruli globally sclerosed, but no immunoreactivity for IgA. 
There was not enough material to perform EM. Since the diagnosis 
of IgA nephropathy was doubtful, genetic diagnostics using the 
FSGS TGP analysis was performed (online suppl. Methods 1 and 
Table 1). This did not lead to a molecular diagnosis. Due to the 
high clinical suspicion, the analysis was expanded to a larger pan-
el of ~225 published renal genes. This revealed a heterozygous 
variant of unknown significance in the HNF1B gene (OMIM189907, 
Table 2) [19–21, 43].
The variant had not been observed before in patients or large 
healthy control populations, in silico predictions suggest a pos-
sible pathogenic effect (Table 2), and the variant segregated in the 
patient’s deceased parent. Laboratory work-up in our patient for 
glucose, electrolyte, and liver enzyme imbalances associated with 
HNF1B-related disease showed no clear abnormalities; however, 
genotype-phenotype correlations can be unclear [44, 45]. The 
HNF1B variant might thus be causal in our patient’s disease and 
the mother’s renal hypodysplasia. This is underscored by studies 
showing that HNF1B works as a modifier on PAX2, in which 
gene mutations are known to cause both isolated congenital 
anomalies of the kidney and urinary tract (CAKUT, such as hy-
podysplasia) as well as FSGS [46–48]. Also, mutations in HNF1B 
sometimes cause a CAKUT phenotype without abnormalities in 
other organs [46, 47]. Hence, it could be that mutations in HNF1B 
also lead to FSGS. Publication of this, to our knowledge first ever, 
case will hopefully stimulate further research into the HNF1B-
FSGS relationship.
Though the patient cannot be conclusively diagnosed, the com-
bination of the variant and the positive family history has led to all 
at-risk family members receiving advice for periodic evaluation of 
renal function.
Discussion
The cases presented in this paper show that although 
the identification of a genetic cause for FSGS presenting 
at an adult age can be complex, an adequate diagnosis can 
have far-reaching implications. That the cases were redi-
agnosed as genetic FSGS is due to the multidisciplinary 
approach with input from a nephrologist, pathologist, 
and clinical geneticist. These specialists discussed the 
possibility of genetic disease and the appropriate applica-
tion of genetic testing for each patient individually. We 
discuss the items at the core of this discussion in detail 
below.
First, it is vital to recognize that though patient char-
acteristics can give clues on patients with high risk of a 
genetic disease, not all patients display those hallmarks 
of genetic disease [8, 9, 11]. Similar to the INF2 case we 
presented, a family history might be absent due to 
germline mosaicism, or mutations that are recessive, de 
Table 2. Molecular diagnosis, including the performed genetic testing and information on the genetic variant, per case







Variant Homozygous or 
heterozygous








Heterozygous Pathogenic Barua et al. [18]
(no functional analysis of this variant)
PolyPhen HumDiv score 1.000, sensitivity
0.00, specificity 1.00
Polyphen HumVar score 1.000, sensitivity
0.00, specificity 1.00
SIFT score 0.13 (tolerated)










PolyPhen HumDiv score 1.000, sensitivity
0.00, specificity 1.00
Polyphen HumVar score 1.000, sensitivity
0.00, specificity 1.00
SIFT score 0.00 (deleterious)













Heterozygous VUS PolyPhen HumDiv score 0.998, sensitivity
0.27, specificity 0.99
PolyPhen HumVar score 0.877, sensitivity
0.71, specificity 0.89
SIFT score 0.04 (deleterious)
Not present in the gnomAD database
Arg, arginine; del, deletion; FSGS, focal segmental glomerulosclerosis; Glu, glutamic acid; Gly, glycine; HGNC, HUGO gene nomenclature committee; His, histidine; OMIM, online 
Mendelian inheritance in man®; Ser, serine; VUS, variant of unknown significance.
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novo or incompletely penetrant [14]. Additionally, 
though a young age at presentation is an indication of 
genetic disease, our COL4A4 patient presented at 50 
years of age [9]. The notion that genetic renal disease 
can present later in life is underscored by our recent 
finding that the classic pediatric disease nephronophthi-
sis actually can present with ESRD to up to 61 years 
[49].
Second, one should consider the appropriate NGS 
scale for each patient. In order to test a sufficient number 
of genes without risk of incidental findings, we apply a 
tiered approach, starting with the analysis of TGPs that 
are limited to strictly FSGS-associated genes. If a limited 
TGP does not yield a diagnosis, one can opt to analyze a 
larger panel (as we did for our HNF1B case), or to perform 
whole-exome sequencing to look for variants in genes not 
yet associated with the patient’s phenotype. To make such 
a step-up process even easier, we decided in 2017 to derive 
all TGP analyses from whole-exome sequencing data. 
Adequate pre- and posttest counseling (described by our 
group previously [38]) regarding analyses of the whole-
exome data should be offered to patients, as these can re-
veal incidental findings.
With the continuous decrease in cost and turn-around 
time of NGS, the precise selection of patients and a step-
up NGS method will likely become less of a question [15]. 
However, genetic testing should always be applied after 
consideration of the prognostic and therapeutic implica-
tions of finding a genetic variant for the patient and his/
her family members.
For the patient, it can provide information on useful 
treatment strategies. Though genetic FSGS generally 
does not respond to corticosteroid treatment, other 
drugs might be beneficial, such as ACE-inhibition in 
COL4A-related disease [42, 50, 51]. Furthermore, a 
 molecular diagnosis is relevant when deliberating on a 
renal transplantation. First, because it usually offers a 
favorable prognosis with respect to recurrence in a re-
nal graft, since chances of this are very low in genetic 
FSGS [52]. Second, if living-related transplantation is 
considered, it is safest to have a genetically unaffected 
family member donate [53]. For this reason, we tested 
the INF2 patient’s parent before proceeding to dona-
tion.
Family members are impacted, as they are at risk of 
also developing FSGS. Those at risk should be offered 
counseling on genetic testing and/or (presymptomatic) 
evaluation of renal function [53]. Likewise, future chil-
dren of a genetic FSGS patient could inherit the disease. 
It is our experience that the knowledge that the disease is 
genetic is very important for patients when contemplat-
ing how to establish their family. As we saw in our INF2 
case, the options for not passing the disease on not only 
include having less or no children but also advanced tech-
niques such as preimplantation genetic diagnostic, when 
locally available [54].
In conclusion, the cases presented in this paper show 
that a genetic diagnosis in adult-onset FSGS can have 
far-reaching consequences not only for the patient but 
also for his/her family (planning). Identification of pa-
tients with a higher likelihood of a genetic FSGS often 
proves challenging, though there are several hallmarks of 
genetic disease. Currently, we apply a tiered method to 
genetic testing, to limit incidental findings. In the future, 
a genetic-first approach could obviate invasive renal bi-
opsies [55]. The probability of a monogenic disease and 
the potential impact of a genetic diagnosis should be 
considered in the diagnostic work-up of all adult-onset 
FSGS cases.
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